Clinical Trials Browser

Unknown × Urinary Bladder Neoplasms × durvalumab × Clear all

Urinary Bladder Neoplasms, Carcinoma, Transitional Cell

NCT05429866 2023-03-08

Immunological Variables Associated to ICI Toxicity in Cancer Patients

BreastDermatologicGastrointestinalGenitourinaryHead & NeckOther solid neoplasmThoracic

Mesothelioma, Malignant, Urinary Bladder Neoplasms, Breast Neoplasms, Carcinoma, Non-Small-Cell Lung, Carcinoma, Renal Cell, Gastrointestinal Neoplasms, Head and Neck Neoplasms, Carcinoma, Hepatocellular, Melanoma, Carcinoma, Merkel Cell, Small Cell Lung Carcinoma

NCT03759496 2022-03-23

Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer

Phase 2 Unknown

39 enrolled

Genitourinary

Urinary Bladder Neoplasms, Neoplasms

Clinical Trials

RADIANT

Immunological Variables Associated to ICI Toxicity in Cancer Patients

Efficacy of Durvalumab in Non-muscle-invasive Bladder Cancer